MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS) today announced that it has closed the previously announced transaction with KV Pharmaceutical Company (“KV”) for the grant of a sublicense of exclusive rights and sale of assets related to EvaMist™, an investigational metered dose transdermal estradiol spray for the treatment of menopause symptoms (the “Transaction”). At the closing, VIVUS received a cash payment of $10 million. All of the closing conditions set forth in the Transaction have been satisfied. The waiting period required by the Federal Trade Commission expired on May 14, 2007 at 11:59 pm eastern time.
